The implementation of a unified strategy for prescribing antipsychotics has proved to be an ineffective approach to the treatment of mentally ill patients. The study of the efficiency of pharmacological drugs on models mimicking the individual pathophysiology of the patient is one means of personalized (predictive) therapy. We evaluated the mRNA level for the genes of the neurotransmitters’ receptors (ADR1B, HRH1, HTR2А, DRD1, DRD2, DRD4, and DRD5). These are targets of antipsychotic drugs; therefore, they can be used as the probable biomarkers of the success of the treatment of mental illnesses of schizophrenic spectrum. We used peripheral blood mononuclear cells (PBMC) in vitro as the therapeutic model. The study included 108 patients with a proved diagnosis of schizophrenia spectrum disorders, receiving a haloperidol or olanzapine as a monotherapy. The patients were divided into two groups based on their response to the pharmacotherapy (effective or ineffective). The response was estimated with psychometric analysis performed on 28 ± 2 days of the treatment. In the group with ineffective therapy, the level of expression of the studied genes in PBMC in vitro had increased with the presence of the antipsychotic drug, while, in the group of patients with positive dynamics of mental status normalization, the analyzed level of expression remained virtually unchanged. The highest significant differences for patients with different responses on the pharmacological treatment were observed for the ADR1B and HRH1 genes in the case of olanzapine therapy (Р = 0.004 and 0.038, respectively) and for the HTR2A gene in the case of haloperidol therapy (Р = 0.039). At the same time, basic levels of gene expression in non-cultivated PBMC were not associated with the patient’s response to therapy. Thus, the mRNA level for genes of neurotransmission in PBMC in vitro in the presence of antipsychotics can be proposed as a biomarker for predicting the pharmacotherapy outcome for mentally ill patients.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
Amare, A.T., Schubert, K.O., and Baune, B.T., Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry, EPMA J., 2017, vol. 8, pp. 211–227.
Andrade, C., Antipsychotic drugs in schizophrenia: relative effects in patients with and without treatment resistance, J. Clin. Psychiatry, 2016, vol. 77, pp. e1656–e1660.
Buttarelli, F.R., Fanciulli, A., Pellicano, C., and Pontieri, F.E., The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders, Curr. Neuropharmacol., 2011, vol. 9, pp. 278–288.
Flaherty, E.K. and Brennand, K.J., Using HiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms, Brain Res., 2017, vol. 1655, pp. 283–293.
Goff, D.C., Romero, K., Paul, J., Perez-Rodriguez, M.M., Crandall, D., and Potkin, S.G., Biomarkers for drug development in early psychosis: current issues and promising directions, Eur. Neuropsychopharmacol., 2016, vol. 26, pp. 923–937.
Kay, S.R., Fiszbein, A., and Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophrenia Bull., 1987, vol. 13, pp. 261–276.
Kennedy, J.L., Altar, C.A., Taylor, D.L., Degtiar, I., and Hornberger, J.C., The social and economic burden of treatment-resistant schizophrenia: a systematic literature review, Int. Clin. Psychopharmacol., 2014, vol. 29, pp. 63–76.
Kozlovskii, V.L., The mechanisms of treatment resistance development in psychiatry in the aspects of pharmacodynamics of psychotropic drugs, Obozr. Psikhiatr. Med. Psikhol. im. V.M. Bekhtereva, 2016, vol. 3, pp. 3–9.
Lai, C.-Y., Scarr, E., Udawela, M., Everall, I., Chen, W.J., and Dean, B., Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics, Word J. Psychiatr., 2014, vol. 6, pp. 102–117.
Lally, J., Wong, Y.L., Shetty, H., Patel, A., Srivastava, V., Broadbent, M.T., and Gaughran, F., Acute hospital service utilization by inpatients in psychiatric hospitals, Gen. Hosp. Psychiatry, 2015, vol. 37, pp. 577–580.
Levite, M., Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, Neurol. Psychiatr. Dis., Acta Physiol., 2016, vol. 216, pp. 42–89.
Morag, A., Kirchheiner, J., Rehavi, M., and Gurwitz, D., Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways, Pharmacogenomics, 2010, vol. 11, pp. 327–340.
Pouget, J.G. and Muller, D.J., Pharmacogenetics of antipsychotic treatment in schizophrenia, Methods Mol. Biol., 2014, vol. 1175, pp. 557–587.
Smith, N., Browning, C.A., Duroudier, N., Stewart, C., Peel, S., Swan, C., Hall, I.P., and Sayers, I., Salmeterol and cytokines modulate inositol-phosphate signaling in human airway smooth muscle cells via regulation at the receptor locus, Resp. Res., 2007, vol. 8, pp. 1–15.
Smith, R.M., Papp, A.C., Webb, A., Ruble, C.L., Munsie, L.M., Nisenbaum, L.K., Kleinman, J.E., Lipska, B.K., and Sadee, W., Multiple regulatory variants modulate expression of 5'-hydroxytryptamine 2A receptors in human cortex, Biol. Psychiatry, 2013, vol. 73, pp. 546–554.
Thibaut, F., Acute treatment of schizophrenia: introduction to the word federation of societies of biological psychiatry guidelines, Psychiatr. Danub., 2014, vol. 26, pp. 2–11.
Wen, Z., Nguyen, H.N., Guo, Z., Lalli, M.A., Wang, X., Su, Y., Kim, N.-S., Yoon, K.-J., Shin, J., Zhang, C., Makri, G., Nauen, D., Yu, H., Guzman, E., Chiang, C.-H., Yoritomo, N., Kaibuchi, K., Zou, J., Christian, K.M., Cheng, L., Ross, C.A., Margolis, R.L., Chen, G., Kosik, K.S., Song, H., and Ming, G.-L., Synaptic dysregulation in a human iPS cell model of mental disorders, Nature, 2014, vol. 515, pp. 414–418.
Young-Pearse, T.L. and Morrow, E.M., Modeling developmental neuropsychiatric disorders with iPS technology: challenges and opportunities, Curr. Opin. Neurobiol., 2016, vol. 36, pp. 66–73.
Zvara, A., Szekeres, G., Janka, Z., Kelemen, J.Z., Cimmer, C., Santha, M., and Puskas, L.G., Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers, Dis. Markers, 2005, vol. 21, pp. 61–69.
This work was carried out within the framework of the state assignment of the Ministry of Health of the Russian Federation “Development of a Personalized Approach for Prescribing Antipsychotic Therapy: Focus on Biogenic Peripheral Blood Monoamines.”
Conflict of interests. The authors declare that they have no conflict of interest.
Statement of compliance with standards of research involving humans as subjects. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants involved in the study.
Translated by I. Shipounova
Abbreviations: PBMC—peripheral blood mononuclear cells, mRNA—messenger RNA, PANSS—positive and negative syndrome scale.
About this article
Cite this article
Grunina, M.N., Zabotina, A.M., Pchelina, M.M. et al. Mononuclear Cells of Peripheral Blood in vitro. A Model of Antipsychotic Therapy Personalization. Cell Tiss. Biol. 13, 64–69 (2019). https://doi.org/10.1134/S1990519X1901005X